Literature DB >> 10749873

Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice.

C Miyaura1, M Inada, T Suzawa, Y Sugimoto, F Ushikubi, A Ichikawa, S Narumiya, T Suda.   

Abstract

Prostaglandin E(2) (PGE(2)) acts as a potent stimulator of bone resorption. In this study, we first clarified in normal ddy mice the involvement of protein kinase A and induction of matrix metalloproteinases (MMPs) in PGE(2)-induced bone resorption, and then identified PGE receptor subtype(s) mediating this PGE(2) action using mice lacking each subtype (EP1, EP2, EP3, and EP4) of PGE receptor. In calvarial culture obtained from normal ddy mice, both PGE(2) and dibutyryl cyclic AMP (Bt(2)cAMP) stimulated bone resorption and induced MMPs including MMP-2 and MMP-13. Addition of an inhibitor of protein kinase A, H89, or an inhibitor of MMPs, BB94, significantly suppressed bone-resorbing activity induced by PGE(2.) In calvarial culture from EP1-, EP2-, and EP3-knockout mice, PGE(2) stimulated bone resorption to an extent similar to that found in calvaria from the wild-type mice. On the other hand, a marked reduction in bone resorption to PGE(2) was found in the calvarial culture from EP4-knockout mice. The impaired bone resorption to PGE(2) was also detected in long bone cultures from EP4-knockout mice. Bt(2)cAMP greatly stimulated bone resorption similarly in both wild-type and EP4-knockout mice. Induction of MMP-2 and MMP-13 by PGE(2) was greatly impaired in calvarial culture from EP4-knockout mice, but Bt(2)cAMP stimulated MMPs induction similarly in the wild-type and EP4-knockout mice. These findings suggest that PGE(2) stimulates bone resorption by a cAMP-dependent mechanism via the EP4 receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749873     DOI: 10.1074/jbc.M002079200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Genetic and pharmacological analysis of prostanoid receptor function.

Authors:  S Narumiya; G A FitzGerald
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Targeting rheumatoid inflammation and joint destruction in the mouse.

Authors:  Masaki Inada; Stephen M Krane
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

3.  In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.

Authors:  S Hu; C C Liu; G Chen; T Willett; R N Young; M D Grynpas
Journal:  Osteoporos Int       Date:  2015-08-14       Impact factor: 4.507

Review 4.  Prostaglandin E(2) receptors in bone formation.

Authors:  M Li; D D Thompson; V M Paralkar
Journal:  Int Orthop       Date:  2007-06-26       Impact factor: 3.075

5.  Sclareol exerts anti-osteoarthritic activities in interleukin-1β-induced rabbit chondrocytes and a rabbit osteoarthritis model.

Authors:  Ying Zhong; Yi Huang; Marcel B Santoso; Li-Dong Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 6.  Infection, inflammation, and bone regeneration: a paradoxical relationship.

Authors:  M V Thomas; D A Puleo
Journal:  J Dent Res       Date:  2011-01-19       Impact factor: 6.116

7.  PGE2 Receptor Subtype 1 (EP1) Regulates Mesenchymal Stromal Cell Osteogenic Differentiation by Modulating Cellular Energy Metabolism.

Authors:  Marina Feigenson; Roman A Eliseev; Jennifer H Jonason; Bradley N Mills; Regis J O'Keefe
Journal:  J Cell Biochem       Date:  2017-05-31       Impact factor: 4.429

8.  The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.

Authors:  Jennifer M McCoy; Joan R Wicks; Laurent P Audoly
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

9.  The remarkable mechanism of prostaglandin E2 on synaptic plasticity.

Authors:  Yukio Akaneya
Journal:  Gene Regul Syst Bio       Date:  2008-05-09

10.  Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.

Authors:  T Ohshiba; C Miyaura; M Inada; A Ito
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.